Selinexor
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 96 patients (estimated)
- Sponsors
- John Theurer Cancer Center at Hackensack University Medical Center
- Collaborators
- Karyopharm Therapeutics
- Tags
- Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1114
- NCT Identifier
- NCT04661137
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.